Diane V Havlir

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint HIV integrase inhibitors--out of the pipeline and into the clinic
    Diane V Havlir
    N Engl J Med 359:416-8. 2008
  2. pmc Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study
    Prashant Kotwani
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California San Francisco, 995 Potrero Avenue, UCSF Box 0874, San Francisco, California 94110, USA
    BMC Public Health 13:1151. 2013
  3. pmc Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance
    Anne F Gasasira
    School of Medicine, Makerere University Kampala, Uganda
    Malar J 9:177. 2010
  4. pmc Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda
    Patrick M Newman
    School of Medicine, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94131, USA
    Malar J 8:254. 2009
  5. pmc Confronting TB/HIV in the era of increasing anti-TB drug resistance
    Jeremiah Chakaya
    Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Africa
    J Int AIDS Soc 11:6. 2008
  6. pmc Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
  7. doi request reprint Opportunities and challenges for HIV care in overlapping HIV and TB epidemics
    Diane V Havlir
    Department of Medicine, University of California, San Francisco, USA
    JAMA 300:423-30. 2008
  8. pmc Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Virol 77:11212-9. 2003
  9. ncbi request reprint Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
  10. pmc Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count
    Gabriel Chamie
    Department of Medicine, University of California, San Francisco, CA, USA
    Clin Infect Dis 51:359-62. 2010

Detail Information

Publications74

  1. doi request reprint HIV integrase inhibitors--out of the pipeline and into the clinic
    Diane V Havlir
    N Engl J Med 359:416-8. 2008
  2. pmc Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study
    Prashant Kotwani
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California San Francisco, 995 Potrero Avenue, UCSF Box 0874, San Francisco, California 94110, USA
    BMC Public Health 13:1151. 2013
    ..Using a community-based strategy that integrated screening for HIV and non-communicable diseases, we determined the prevalence, awareness, treatment rates, and sociodemographic factors associated with hypertension in rural Uganda...
  3. pmc Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance
    Anne F Gasasira
    School of Medicine, Makerere University Kampala, Uganda
    Malar J 9:177. 2010
    ..This study assessed the incidence of falciparum malaria and the prevalence of resistance-conferring Plasmodium falciparum mutations in HIV-infected children receiving daily TS and HIV-uninfected children not taking TS...
  4. pmc Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda
    Patrick M Newman
    School of Medicine, University of California, San Francisco, 513 Parnassus Ave, San Francisco, CA 94131, USA
    Malar J 8:254. 2009
    ..TS decreases the risk of malaria in HIV-infected adults and children but has not been evaluated among pregnant women...
  5. pmc Confronting TB/HIV in the era of increasing anti-TB drug resistance
    Jeremiah Chakaya
    Centre for Respiratory Diseases Research, Kenya Medical Research Institute, Africa
    J Int AIDS Soc 11:6. 2008
    ..These interventions are best carried out by HIV control programmes which should therefore be encouraged to take greater responsibility in implementing these interventions...
  6. pmc Timing of antiretroviral therapy for HIV-1 infection and tuberculosis
    Diane V Havlir
    University of California, San Francisco, 995 Potrero Ave, Bldg 80, Ward 84, San Francisco, CA 94110 2897, USA
    N Engl J Med 365:1482-91. 2011
    ....
  7. doi request reprint Opportunities and challenges for HIV care in overlapping HIV and TB epidemics
    Diane V Havlir
    Department of Medicine, University of California, San Francisco, USA
    JAMA 300:423-30. 2008
    ....
  8. pmc Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California 94110, USA
    J Virol 77:11212-9. 2003
    ....
  9. ncbi request reprint Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine
    Diane V Havlir
    Department of Medicine, San Francisco General Hospital, University of California at San Francisco, San Francisco, California, USA
    J Infect Dis 191:1164-8. 2005
    ..05). However, a level of residual viremia <50 copies/mL was not associated with CD4 cell count changes or risk of virologic rebound through 72 weeks of follow-up...
  10. pmc Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count
    Gabriel Chamie
    Department of Medicine, University of California, San Francisco, CA, USA
    Clin Infect Dis 51:359-62. 2010
    ..Trial registration. ClinicalTrials.gov identifier: NCT00078247 ...
  11. doi request reprint Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA Makerere University University of California, San Francisco Research Collaboration, Kampala, Uganda Makerere University Joint AIDS Program, Kampala, Uganda Division of Biostatistics, University of California, Berkeley, Berkeley, CA Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, Chapel Hill, NC Center for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco, San Francisco, CA and Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
    J Acquir Immune Defic Syndr 65:327-32. 2014
    ..In a rural Ugandan community scaling up antiretroviral therapy (ART), we sought to determine if population-based HIV RNA levels [population viral load (VL)] decreased from 2011 to 2012...
  12. pmc Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda
    Gabriel Chamie
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 7:e43400. 2012
    ..We tested the feasibility and diagnostic yield of integrating NCD and communicable diseases into a rapid HIV testing and referral campaign for all residents of a rural Ugandan parish...
  13. pmc The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting
    Elvin H Geng
    Division of HIV AIDS at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, California, USA
    Clin Infect Dis 55:1690-7. 2012
    ..The effect of changing guidance on real-world patient outcomes has not been evaluated...
  14. pmc Sex differences in HIV RNA level and CD4 cell percentage during childhood
    Theodore D Ruel
    Department of Pediatrics, University of California, San Francisco, California, USA
    Clin Infect Dis 53:592-9. 2011
    ..Limited data exist regarding potential sex differences in HIV RNA level and CD4 parameters among prepubertal children with untreated HIV infection...
  15. pmc Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs
    Anne F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA Department of Medicine, College of Medicine, Blantyre, Malawi Faculty of Heath Sciences, University of the Witwatersrand, Johannesburg, South Africa Division of Infectious Diseases, School of Medicine, University of California, San Diego, CA and Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE
    J Acquir Immune Defic Syndr 65:423-8. 2014
    ..later ART (8-12 weeks after TB treatment) in HIV-infected patients starting TB treatment...
  16. ncbi request reprint Evaluating linkage to care for hypertension after community-based screening in rural Uganda
    Prashant Kotwani
    Division of HIV AIDS, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, USA Makerere University University of California San Francisco Research Collaboration, Mbarara, Kampala, Uganda
    Trop Med Int Health 19:459-68. 2014
    ..To determine the frequency and predictors of hypertension linkage to care after implementation of a linkage intervention in rural Uganda...
  17. pmc Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study
    Anne F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 57:586-93. 2013
    ....
  18. pmc Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco UCSF, San Francisco, CA 94143 0874, USA
    Clin Infect Dis 56:598-605. 2013
    ..We estimated population-based HIV RNA levels using a fingerprick-based approach in a rural Ugandan community implementing rapid ART scale-up...
  19. pmc Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter
    Steven A Yukl
    San Francisco VA Medical Center, San Francisco, CA 94121, USA
    J Virol Methods 175:261-5. 2011
    ..77 copy/ml; 95% CI 0.86-4.68 copy/ml). The measured viral load correlated inversely (r = -0.78; p = 0.028) with the total duration of viral suppression (viral load<40 copies/ml)...
  20. pmc Effect of left ventricular dysfunction and viral load on risk of sudden cardiac death in patients with human immunodeficiency virus
    Brian S Moyers
    Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California, San Francisco, San Francisco, California
    Am J Cardiol 113:1260-5. 2014
    ..Further investigation is needed to thoroughly evaluate the effect of low EF and HIV factors on SCD incidence and the potential benefit of implantable cardioverter-defibrillator therapy in this high-risk population...
  21. pmc The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence
    Steven A Yukl
    Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco
    J Infect Dis 208:1212-20. 2013
    ..Future studies should determine whether different mechanisms allow HIV to persist in these distinct reservoirs, and the degree to which different therapies can affect each reservoir...
  22. pmc Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda
    Harsha Thirumurthy
    Department of Health Policy and Management, University of North Carolina, Chapel Hill, NC, USA
    AIDS 27:627-34. 2013
    ..We examined this association among adults in a rural Ugandan parish...
  23. pmc Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS
    Tara Vijayan
    Division of Infectious Diseases, University of California, San Francisco
    Clin Infect Dis 57:1766-72. 2013
    ....
  24. pmc Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children
    Theodore D Ruel
    Department of Pediatrics, School of Medicine, University of California, San Francisco, San Francisco, CA 94143 0136, USA
    J Acquir Immune Defic Syndr 56:44-50. 2011
    ..We sought to determine the prevalence of early virologic failure (EVF), to characterize the evolution of ARV-resistance mutations and to predict the impact on second-line therapy...
  25. pmc Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda
    Gabriel Chamie
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, United States of America Makerere University University of California San Francisco MU UCSF Research Collaboration, Uganda The Sustainable East Africa Research in Community Health SEARCH Consortium
    PLoS ONE 9:e84317. 2014
    ..However, a greater understanding of population-level uptake is needed to maximize effectiveness of this approach...
  26. ncbi request reprint Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda
    Padmini Srikantiah
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 21:1972-4. 2007
    ..No cases of hypersensitivity or immune reconstitution syndrome were observed. These data support the continuing evaluation of nucleoside-based antiretroviral regimens as an alternative treatment for this population...
  27. pmc Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts
    Theodore D Ruel
    Division of Infectious Disease, Department of Pediatrics, UCSF Benioff Children s Hospital, University of California, San Francisco, CA 94143 0136, USA
    Clin Infect Dis 54:1001-9. 2012
    ....
  28. pmc Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy
    Edwin D Charlebois
    School of Medicine, University of California, San Francisco, CA 94105, USA
    J Acquir Immune Defic Syndr 55:330-5. 2010
    ..Increasing numbers of HIV-infected children not yet eligible for antiretroviral therapy (ART) are entering health care in Africa. We sought to characterize the risk of short-term disease progression in this population...
  29. pmc Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
    J Infect Dis 202:1553-61. 2010
    ..The gut is a major reservoir for human immunodeficiency virus (HIV) in patients receiving antiretroviral therapy (ART). We hypothesized that distinct immune environments within the gut may support varying levels of HIV...
  30. doi request reprint A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells
    Steven A Yukl
    aSan Francisco Veterans Affairs Medical Center bUniversity of California, San Francisco UCSF, California, USA
    AIDS 28:439-42. 2014
    ..HIV DNA levels in total rectal cells were greater than those predicted from levels in sorted CD4 T cells, suggesting a reservoir in non-CD4 T cells, and HIV DNA was detected in sorted myeloid cells (7/7 subjects)...
  31. pmc Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy
    Steven A Yukl
    San Francisco VA Medical Center SFVAMC and University of California, San Francisco UCSF, San Francisco, California, USA
    AIDS 24:2451-60. 2010
    ..To determine whether raltegravir-containing antiretroviral therapy (ART) intensification reduces HIV levels in the gut...
  32. pmc Complications of HIV disease and antiretroviral treatment
    Anne F Luetkemeyer
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 18:57-65. 2010
    ..This year's conference also highlighted important data on prevention and optimal treatment of common coinfections that occur in HIV-infected individuals, including tuberculosis, influenza, and viral hepatitis...
  33. pmc Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB
    Anne F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, California, USA
    J Clin Microbiol 52:1052-9. 2014
    ..tuberculosis identification with the Direct LPA and 44.1% sensitivity with MTBDR-Plus. LPAs have a continued role for use in settings where rapid identification of INH resistance and clinically relevant NTM are priorities. ..
  34. pmc The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation
    Elvin H Geng
    Division of HIV AIDS, San Francisco General Hospital, and Department of Medicine, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Clin Infect Dis 53:1008-14. 2011
    ..Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164...
  35. ncbi request reprint Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1
    Matthew C Strain
    Department of Physics, University of California at San Diego, La Jolla, California, USA
    J Infect Dis 191:1410-8. 2005
    ..1 IUPM; P<.0005). These results suggest that treatment <6 months after seroconversion may facilitate long-term control of cellular reservoirs that maintain HIV-1 infection during treatment...
  36. pmc Tuberculosis drug development: ensuring people living with HIV are not left behind
    Anne F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 184:1107-13. 2011
    ....
  37. ncbi request reprint CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy
    Anne F Luetkemeyer
    University of California San Francisco, San Francisco, CA, USA
    Top Antivir Med 21:62-74. 2013
    ..Finally, the conference provided important information on tuberculosis coinfection and cryptococcal meningitis...
  38. pmc Tuberculosis as part of the natural history of HIV infection in developing countries
    Gabriel Chamie
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, USA
    Clin Infect Dis 50:S245-54. 2010
    ..Investment in this research will improve the lives of persons infected with HIV and contribute to efforts to reduce the global TB burden...
  39. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, CA, USA
    Top HIV Med 14:27-35. 2006
    ..This review will summarize information on complications of antiretroviral therapy in resource-limited settings, hepatitis C virus, tuberculosis, and discussion of metabolic, cardiovascular, and renal complications...
  40. pmc Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding
    Monica Gandhi
    Department of Medicine, University of California, San Francisco, San Francisco, CA Infectious Diseases Research Collaboration, Makerere University College of Health Sciences University of California, San Francisco, Kampala, Uganda Department of Clinical Pharmacy Center for AIDS Prevention Studies Departments of Pediatrics Bioengineering and Therapeutic Sciences and Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA
    J Acquir Immune Defic Syndr 63:578-84. 2013
    ..We measured plasma and hair antiretroviral levels in HIV-infected Ugandan mothers and their infants at delivery and during breastfeeding to assess transfer...
  41. ncbi request reprint Responding to organ failure in HIV-infected patients
    Michelle E Roland
    AIDS Division, Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, USA
    N Engl J Med 348:2279-81. 2003
  42. pmc Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis
    J Lucian Davis
    Department of Medicine, San Francisco General Hospital and University of California, San Francisco, California 94110, USA
    Clin Infect Dis 48:725-32. 2009
    ..Few studies have assessed their performance among patients infected with HIV, and no studies have assessed their performance with oral wash specimens, which may be easier to obtain than sputum samples...
  43. ncbi request reprint Strategic approaches to antiretroviral treatment
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:145-9. 2003
    ..This article summarizes a presentation given by Diane V. Havlir, MD, at the March 2003 International AIDS Society-USA course in Los Angeles...
  44. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Anne F Luetkemeyer
    University of California San Francisco, USA
    Top Antivir Med 20:48-60. 2012
    ....
  45. ncbi request reprint Intensive care of patients with HIV infection
    Laurence Huang
    HIV AIDS Division, San Francisco General Hospital, University of California San Francisco, San Francisco, USA
    N Engl J Med 355:173-81. 2006
  46. ncbi request reprint A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    Constance A Benson
    University of California, San Diego School of Medicine, San Diego, CA 92103, USA
    J Infect Dis 194:1309-18. 2006
    ..The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain...
  47. ncbi request reprint Nontuberculous mycobacteria in the HIV infected patient
    Denis Jones
    School of Medicine, University of California, Mail Code 8208, 150 W Washington Street, 100, San Diego, CA 92103, USA
    Clin Chest Med 23:665-74. 2002
    ..Clinicians treating HIV-infected patients must remain familiar with the diagnosis and treatment of these diseases and implement prevention strategies when indicated...
  48. pmc Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy
    C Bradley Hare
    Dept of Medicine, University of California, San Francisco, CA 94110, USA
    Clin Infect Dis 47:421-4. 2008
    ..Mutations remained detectable for at least 48 weeks in some subjects...
  49. pmc Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors
    Sunil Parikh
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, Box 0811, San Francisco, California 94110, USA
    Antimicrob Agents Chemother 49:2983-5. 2005
    ..Lopinavir also inhibited the P. falciparum aspartic protease plasmepsin II at a similar concentration (IC50, 2.7 microM). These findings suggest that use of HIV-1 protease inhibitors may offer clinically relevant antimalarial activity...
  50. doi request reprint Acceptability and feasibility of serial HIV antibody testing during pregnancy/postpartum and male partner testing in Tororo, Uganda
    Lena H Kim
    a The Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA
    AIDS Care 26:360-6. 2014
    ..05). In conclusion, partial serial HIV testing was highly acceptable and feasible, but completion of serial testing and male partner testing had poor uptake...
  51. pmc The end of AIDS: HIV infection as a chronic disease
    Steven G Deeks
    Department of Medicine, University of California, San Francisco, CA, USA Electronic address
    Lancet 382:1525-33. 2013
    ..In view of the problems inherent in the treatment and care for patients with a chronic disease that might persist for several decades, a global effort to identify a cure is now underway. ..
  52. ncbi request reprint Complications of HIV infection and antiretroviral therapy
    Diane V Havlir
    University of California San Francisco, San Francisco, CA, USA
    Top HIV Med 11:86-91. 2003
  53. pmc Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes
    Peilin Li
    University of California, San Francisco UCSF, Department of Medicine, San Francisco, CA 94121, USA
    J Virol Methods 170:115-20. 2010
    ..765, p<0.0001). This approach to Taqman probe design should be explored further for use in diagnosis and monitoring of HIV in resource-limited settings, especially where several subtypes co-circulate...
  54. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Anne F Luetkemeyer
    University of California San Francisco, San Francisco, CA, USA
    Top Antivir Med 19:58-68. 2011
    ....
  55. ncbi request reprint CROI 2014: viral hepatitis and complications of HIV disease and antiretroviral therapy
    Anne F Luetkemeyer
    University of California San Francisco and San Francisco General Hospital, San Francisco, CA, USA
    Top Antivir Med 22:602-15. 2014
    ..Finally, new data on novel drugs and combinations for treatment of tuberculosis (TB), patient outcomes using new rapid TB diagnostics, and a short-course TB prevention strategy were presented. ..
  56. pmc Sudden cardiac death in patients with human immunodeficiency virus infection
    Zian H Tseng
    Section of Cardiac Electrophysiology, Division of Cardiology, University of California San Francisco, San Francisco, CA 94313, USA
    J Am Coll Cardiol 59:1891-6. 2012
    ..The aim of this study was to determine the incidence and clinical characteristics of sudden cardiac death (SCD) in patients with human immunodeficiency virus (HIV) infection...
  57. pmc The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco
    Edwin D Charlebois
    HIV AIDS Division, Department of Medicine, San Francisco General Hospital, California, USA
    Clin Infect Dis 52:1046-9. 2011
    ..Addition of annual HIV testing for men who have sex with men to universal treatment decreases new infections by 76%...
  58. pmc Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals
    Annie F Luetkemeyer
    HIV AIDS Division, San Francisco General Hospital, University of California at San Fracisco, San Francisco, Box 0874, Building 80, 995 Potrero Avenue, San Francisco, CA 94110, USA
    Am J Respir Crit Care Med 175:737-42. 2007
    ..Although interferon (IFN)-gamma release assays are approved for the diagnosis of latent tuberculosis infection (LTBI), limited data exist regarding their performance in HIV infection...
  59. ncbi request reprint Atazanavir: new option for treatment of HIV infection
    Diane V Havlir
    San Francisco General Hospital, University of California, San Francisco, California, USA
    Clin Infect Dis 38:1599-604. 2004
    ..Similar to other protease inhibitors, careful attention must be paid to drug interactions when administering atazanavir with concomitant medications...
  60. pmc Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?
    Diane V Havlir
    Division of Infectious Diseases, University of California, 150 West Washington Street, Suite 100, San Diego, CA 92103, USA
    Proc Natl Acad Sci U S A 99:4-6. 2002
  61. ncbi request reprint Patents versus patients? Antiretroviral therapy in India
    Diane V Havlir
    University of California, San Francisco, USA
    N Engl J Med 353:749-51. 2005
  62. ncbi request reprint Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression
    Victor Appay
    Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    AIDS 16:161-70. 2002
    ..It leads to significant reductions of plasma viremia, often to undetectable levels, but it can also be linked with the reduction and disappearance of detectable HIV-specific CD8 T-cell responses...
  63. ncbi request reprint Antiretroviral therapy and TB
    Soumya Swaminathan
    Division of HIV AIDS, Tuberculosis Research Centre, Chennai, India
    Trop Doct 36:73-9. 2006
    ..Despite the complexities presented by co-infection, many programmes have integrated care and are successfully treating patients with both HIV and TB...
  64. ncbi request reprint Complications of HIV disease and antiretroviral therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 13:16-23. 2005
    ....
  65. pmc HIV RNA suppression among HIV-infected Ugandan children with measles
    Theodore D Ruel
    J Acquir Immune Defic Syndr 48:225-7. 2008
  66. ncbi request reprint Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 12:31-45. 2004
    ..This article summarizes these presentations...
  67. ncbi request reprint Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy
    Kara K Bennett
    SDAC, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Acquir Immune Defic Syndr 31:20-6. 2002
    ..01) had higher increases in phase I changes. Phase II CD4 cell counts did not depend solely on baseline HIV-1 RNA levels and CD4 cell counts but on their interaction (p =.0001) as well as on achieving virologic suppression (p =.0009)...
  68. ncbi request reprint Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics
    Padmini Srikantiah
    J Infect Dis 191:147-9. 2005
  69. ncbi request reprint Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170
    Daniel J Skiest
    Baystate Medical Center, Springfield, MA 01106, USA
    J Infect Dis 195:1426-36. 2007
    ..We sought to determine the safety of treatment interruption (TI) and to identify parameters that would define patients with human immunodeficiency virus (HIV) for whom TI is safer...
  70. ncbi request reprint Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials
    Francois Xavier Blanc
    Agence Nationale de Recherches sur le Sida et les Hepatites Virales, Paris, France
    J Infect Dis 196:S46-51. 2007
    ..Here, we present an overview of these ongoing or planned clinical studies, which are supported by international agencies...
  71. ncbi request reprint High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
    ..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects...
  72. ncbi request reprint The case for earlier treatment of HIV infection
    Scott D Holmberg
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Clin Infect Dis 39:1699-704. 2004
    ..Given these accumulating data, we believe reconsideration of the "when-to-start" question is timely and justified...
  73. ncbi request reprint Complications of HIV disease and therapy
    Judith S Currier
    University of California Los Angeles, Los Angeles, CA, USA
    Top HIV Med 15:40-7. 2007
    ..As the field of clinical research in HIV continues to mature, we are repeatedly surprised by the findings from well-designed studies...
  74. ncbi request reprint Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
    Victor Appay
    MRC Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Med 8:379-85. 2002
    ..These findings challenge the current definitions of memory and effector subsets in humans, and suggest that ascribing effector and memory functions to subsets with different differentiation phenotypes is no longer appropriate...